Read More 1 minute read Analyst Ratings News Price Target Upgrades Cowen & Co. Upgrades Delta Air Lines to Outperform, Announces $54 Price Target By Benzinga Newsdesk October 14, 6:34 AM Cowen & Co. analyst Helane Becker upgrades Delta Air Lines (NYSE:DAL) from Market Perform to Outperform and announces $54 price target. DAL
Read More 1 minute read Analyst Ratings News Price Target Upgrades Jefferies Upgrades Harmony Biosciences to Buy, Raises Price Target to $61 By Benzinga Newsdesk October 14, 6:25 AM Jefferies analyst Chris Howerton upgrades Harmony Biosciences (NASDAQ:HRMY) from Hold to Buy and raises the price target from $57 to $61. HRMY
Read More 1 minute read Analyst Ratings News Price Target Upgrades Mizuho Upgrades Avangrid to Neutral, Announces $39 Price Target By Benzinga Newsdesk October 14, 6:21 AM Mizuho analyst Paul Fremont upgrades Avangrid (NYSE:AGR) from Underperform to Neutral and announces $39 price target. AGR
Read More 1 minute read Analyst Ratings News Price Target Tech Upgrades US Cable Is Down But Not Out. Favorable Cash Flow Is The Silver Lining, Comcast Analyst Says By Anusuya Lahiri October 13, 2:58 PM Citi analyst Michael Rollins upgraded Comcast Corp (NASDAQ:CMCSA) to Buy from Neutral with a price target of $36, down from $42. Cable… CMCSA
Read More 1 minute read Analyst Ratings Biotech General Health Care Large Cap Movers News Trading Ideas Upgrades Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts By Vandana Singh October 13, 1:45 PM Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. BIIB
Read More 1 minute read Analyst Ratings News Price Target Upgrades Citigroup Upgrades Altice USA to Buy, Lowers Price Target to $8 By Benzinga Newsdesk October 13, 7:45 AM Citigroup analyst Michael Rollins upgrades Altice USA (NYSE:ATUS) from Neutral to Buy and lowers the price target from $12 to $8. ATUS
Read More 1 minute read Analyst Ratings News Price Target Upgrades Guggenheim Upgrades Ultragenyx Pharmaceutical to Buy, Announces $50 Price Target By Benzinga Newsdesk October 13, 7:28 AM Guggenheim analyst Debjit Chattopadhyay upgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Neutral to Buy and announces $50 price target. RARE
Read More 1 minute read Analyst Ratings News Price Target Upgrades Guggenheim Upgrades BeiGene to Buy, Announces $205 Price Target By Benzinga Newsdesk October 13, 7:27 AM Guggenheim analyst Michael Schmidt upgrades BeiGene (NASDAQ:BGNE) from Neutral to Buy and announces $205 price target. BGNE
Read More 1 minute read Analyst Ratings News Price Target Upgrades B of A Securities Upgrades Las Vegas Sands to Neutral, Announces $37 Price Target By Benzinga Newsdesk October 13, 7:23 AM B of A Securities analyst Shaun Kelley upgrades Las Vegas Sands (NYSE:LVS) from Underperform to Neutral and announces $37 price target. LVS
Read More 1 minute read Analyst Ratings News Price Target Upgrades JP Morgan Upgrades Colgate-Palmolive to Overweight, Announces $79 Price Target By Benzinga Newsdesk October 13, 6:12 AM JP Morgan analyst Andrea Teixeira upgrades Colgate-Palmolive (NYSE:CL) from Neutral to Overweight and announces $79 price target. CL